我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

替米沙坦对伴有冠心病的原发性高血压患者左室重构、C反应蛋白及心功能的影响

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2010年第5期
页码:
747-750，757
栏目:
临床研究
出版日期:
2010-06-22

文章信息/Info

Title:
Effects of telmisartan on the levels of hs-CRP, left ventricular remodeling and left ventricular function in patients with essential hypertension and coronary heart disease
作者:
李庆辉1; 2; 杨天伦2; 谭碧峰3; 周环2; 周波2
1.湖南农业大学医院心内科， 湖南 长沙 410128；2.中南大学湘雅医院心内科,湖南 长沙 410008；3.怀化医学院附属怀化市第三人民医院心内科，湖南 怀化 418000
Author(s):
LI Qing-hui1; 2;  YANG Tian-lun2;  TAN Bi-feng3;  ZHOU Huan2;  ZHOU Bo2
1.Department of Cardiology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; 2.Department of Cardiology, Third People’s Hospital of Huaihua City, Huaihua Medical College, Huaihua 410008, Hunan, China
关键词:
替米沙坦; 高血压病; 原发性; 左心室肥厚; 冠状动脉疾病; C反应蛋白
Keywords:
telmisartan;  essential hypertension;  left ventricular hypertrophy;  coronary disease;  C- reactive protein
分类号:
R544. 1
DOI:
-
文献标识码:
A
摘要:
目的：探讨替米沙坦对伴有冠心病的原发性高血压(EH)患者左室重构、超敏-C反应蛋白(hs-CRP)及心功能的影响。方法： 选择并发有冠心病的原发性高血压患者120例，随机分为替米沙坦组（49例）和贝那普利组（44例），分别予以替米沙坦口服（80～160 mg/d）和贝那普利口服（10～20 mg/d），每日1次,疗程均为24 周，治疗前后分别测血压、血脂、尿酸(UA)、hs-CRP和超声心动图测定左室结构和功能，对比分析治疗前、后各指标的差异。结果： ①与治疗前比较,替米沙坦组和贝那普利组治疗后收缩压和舒张压明显下降(161/101至130/83 mmHg；160/102至131/85 mmHg,均为P<0.01)；②替米沙坦治疗后,三酰甘油(TG)、舒张期室间隔厚度(IVST)、舒张期左室后壁厚度(LVPWT)、左室舒张末内径（LVEDD）、A/E明显降低(P<0.05)；UA、左室射血分数(LVEF)、hs-CRP及左室质量指数(LVMI)下降非常显著（P<0.01）；贝那普利组治疗后无明显的变化,但hs-CRP、LVMI明显下降（P<0.05）；两组治疗后比较，替米沙坦组UA、LVMI明显下降及LVEF明显改善（P<0.05）；③直线相关分析显示：hs-CRP与LVMI呈正相关（r=0.61,P<0.05）。结论： 替米沙坦和贝那普利均能有效降低EH患者的血压水平。与贝那普利比较，替米沙坦还能显著降低hs-CRP水平以及改善三酰甘油代谢和血UA代谢,并使EH患者LVH显著逆转和心功能明显改善。
Abstract:
AIM: To investigate the effects of telmisartan on the levels of high sensitivity CRP (hs-CRP), left ventricular remodeling and left ventricular functions in patients with essential hypertension and coronary heart disease. METHODS: One hundred and twenty patients with coronary heart disease and essential hypertension with left ventricular hypertrophy (LVH) were randomized into the telmisartan group (49 cases) or benazepri group(44 cases) and were treated with telmisartan (80-160 mg/d) or benazepril (10-20 mg/d). The patients were followed-up for 24 weeks and the levels of cholesterol, fasting plasma glucose (FPG), uric acid (UA) and hs-CRP were measured before and after treatment. Color Doppler echocardiography was used to study the left ventricular structure and functions. RESULTS: After 24 weeks of treatment with telmisartan or benazepril, blood pressure reduced from 161/101 to 130/83 mmHg (P<0.01) or from 160/102 to 131/85 mmHg (P<0.01) respectively. At the end of 24 weeks, significant decrease was observed in TG, IVST, LVPWT, LVDd and A/E (P<0.05), as well as in UA, LVEF, hs-CRP and LVMI (P<0.01) in patients treated with telmisartan. In patients treated with benazepril, significant decrease was seen only in hs-CRP and LVMI (P<0.05). No significant changes were observed in total cholesterol, HDL-C and LDL-C in either group. Linear regression analysis indicated that hs-CRP was strongly associated with LVMI (P<0.05). CONCLUSION: Telmisartan and benazepri are all effective in reducing blood pressure, But telmisartan is better than benazepri in regulating the levels of TG, UA, hs-CRP, and improving left ventricular functions and reversing LVH.

参考文献/References

［1］Verdechia P, Porcella C, Reboldi G, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension［J］. Circulation, 2001, 104(17):2039-2044.

［2］Smith DH. Comparison of angiotensin Ⅱtype 1 receptor antagonists in the treatment of essential hypertension［J］. Drugs, 2008, 68(9):1207-1225.

［3］European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European society of hypertension-European society of cardiology guidelines for the management of arterial hypertension［J］. Hypertens, 2003, 21(6):1011-1053.

［4］Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity［J］. Hypertension, 2004, 43(5):993-1002.

［5］Brown JD, Plutzky J. Peroxisome proliferators-activated receptors as tran-scriptional nodal points and therapeutic targets［J］. Circulation, 2007, 115(4)：518-533．

［6］景晓娟，赵连友，章燕，等. 氨氯地平联合替米沙坦及复方盐酸阿米洛利治疗高血压和左室肥厚的效果及其与瘦素的关系［J］. 心脏杂志， 2009， 21(3)：367-370,374.

［7] Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension［J］. Drugs, 2006, 66(1):81-83.

［8］ Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory marles and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study［J］. Circulation, 2003, 107(11):1485-1491.

[9] Assadi F. Effect of microalbuminuria-lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension［J］. Pediatr Cardiol, 2007, 28(1)：27-33．

[10]Derosa G, Ragones PD, Mugellini A, et al. Effects of telmisartan compared with eprosartan on blood pressure control glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo- placebo-controlled 12-month study［J］. Hypertens Res, 2004, 27(7):457-464.

[11]Puig JG, Torres R, Ruiloper LM. AT1 blockers and uric acid metabolism: are there relevant differences?［J］. Hypertension, 2002, 20（5）:S29-S31.

[12]杨飞燕，陈曼华，余波. 血尿酸和左室质量指数与高血压病患者心血管事件发生率有关［J］. 心脏杂志， 2008， 20(4):442-443,446.

［13］Sica DA, Schoolwerth AC. Part 1. Uric acid and losartan［J］. Curr Opin Nephrol Hypertens, 2002， 11(5):475-482.

备注/Memo

备注/Memo:
收稿日期：2009-12-15.通讯作者：杨天伦，教授，主要从事高血压、冠心病防治基础与临床研究Email:tianluny@163.com 作者简介：李庆辉,主治医师，硕士Email:liqinghui_127@sina.com
更新日期/Last Update: 2010-06-22